Opens in a new tab or window Glenmark Pharma recalled 1.48 million bottles of the generic attention deficit-hyperactivity disorder (ADHD) drug atomoxetine due to the presence of a possible carcinogen.

Glenmark Pharmaceuticals, an India-based drug manufacturer has issued a voluntary recall affecting nearly 1.48 million bottles of atomoxetine, a generic medication used to treat ADHD. The recall ...

Unlike stimulant-based drugs that make up the bulk of ADHD treatment, including those like Vyvanse and Adderall, atomoxetine is a selective norepinephrine reuptake inhibitor (sNRI). The recall was ...

It's reported more than 8 million Americans take a blood thinner. One has been recalled for potential absorption issues.

Stimulants are the most common ADHD medications, but they don’t work for everyone. Nonstimulants have fewer side effects but take longer to work. If you have attention deficit hyperactivity ...

According to the U.S. health agency, Glenmark Pharmaceuticals is recalling over 15 lakh bottles of a generic drug used to treat ... various strengths are being recalled by Glenmark Pharmaceuticals ...

A new study finds that nearly half of the most popular ADHD videos on TikTok share misleading claims that don't match official diagnoses. The study, published Wednesday in PLOS One, explored TikTok's ...

Glenmark Pharma recalls 114 batches of hypokalemia drug in U.S. The recall is due to ... of serious adverse health consequences is remote. ADHD is a neurodevelopmental disorder that affects ...